X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (552) 552
tegafur - administration & dosage (414) 414
male (390) 390
female (366) 366
middle aged (350) 350
oncology (343) 343
aged (340) 340
drug combinations (316) 316
5-fluorouracil (255) 255
antineoplastic combined chemotherapy protocols - therapeutic use (254) 254
adult (240) 240
index medicus (228) 228
tegafur - pharmacokinetics (218) 218
s-1 (206) 206
oxonic acid - administration & dosage (195) 195
chemotherapy (193) 193
administration, oral (191) 191
uracil - administration & dosage (178) 178
cancer (158) 158
fluorouracil (154) 154
tegafur - adverse effects (146) 146
stomach neoplasms - drug therapy (145) 145
tegafur (139) 139
treatment outcome (138) 138
pharmacology & pharmacy (136) 136
tegafur - therapeutic use (129) 129
antineoplastic combined chemotherapy protocols - adverse effects (122) 122
drug administration schedule (122) 122
antineoplastic combined chemotherapy protocols - administration & dosage (120) 120
pharmacokinetics (116) 116
fluorouracil - pharmacokinetics (113) 113
fluorouracil - administration & dosage (105) 105
animals (104) 104
colorectal neoplasms - drug therapy (104) 104
oxonic acid - adverse effects (101) 101
oxonic acid - pharmacokinetics (100) 100
uft (94) 94
antimetabolites, antineoplastic - administration & dosage (93) 93
antimetabolites, antineoplastic - pharmacokinetics (91) 91
antineoplastic combined chemotherapy protocols - pharmacokinetics (91) 91
aged, 80 and over (82) 82
fluorouracil - blood (82) 82
oxonic acid - therapeutic use (81) 81
carcinoma (79) 79
trial (78) 78
colorectal cancer (77) 77
leucovorin (77) 77
stomach neoplasms - pathology (76) 76
gastric cancer (74) 74
uracil - pharmacokinetics (74) 74
capecitabine (70) 70
leucovorin - administration & dosage (70) 70
adenocarcinoma - drug therapy (66) 66
antitumor-activity (65) 65
cisplatin (64) 64
neoplasm staging (64) 64
dose-response relationship, drug (63) 63
survival rate (63) 63
uracil (62) 62
antimetabolites, antineoplastic - therapeutic use (61) 61
care and treatment (61) 61
research (59) 59
medicine & public health (54) 54
rats (53) 53
antimetabolites, antineoplastic - adverse effects (51) 51
stomach cancer (51) 51
adjuvant chemotherapy (50) 50
irinotecan (50) 50
phase-ii (50) 50
pyridines - administration & dosage (50) 50
tegafur - blood (50) 50
camptothecin - analogs & derivatives (49) 49
fluorouracil - analogs & derivatives (49) 49
chemotherapy, adjuvant (48) 48
deoxycytidine - analogs & derivatives (48) 48
toxicity (48) 48
maximum tolerated dose (47) 47
mice (47) 47
oxaliplatin (47) 47
disease-free survival (46) 46
tegafur - pharmacology (46) 46
colorectal neoplasms - pathology (45) 45
combined modality therapy (45) 45
therapy (45) 45
1st-line treatment (44) 44
clinical study (44) 44
fluorouracil - therapeutic use (44) 44
metastasis (44) 44
neoplasms - drug therapy (44) 44
area under curve (43) 43
camptothecin - administration & dosage (43) 43
dihydropyrimidine dehydrogenase (43) 43
neoplasm metastasis (43) 43
liver neoplasms - drug therapy (42) 42
lung neoplasms - drug therapy (42) 42
pharmacology/toxicology (42) 42
prognosis (42) 42
drug therapy (41) 41
pyridines - pharmacokinetics (41) 41
stomach neoplasms - surgery (41) 41
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (541) 541
Japanese (115) 115
Chinese (3) 3
Korean (2) 2
Russian (2) 2
German (1) 1
Norwegian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecules, ISSN 1420-3049, 09/2017, Volume 22, Issue 9, p. 1488
Journal Article
Journal Article
Cancer Medicine, ISSN 2045-7634, 12/2017, Volume 6, Issue 12, pp. 2909 - 2917
S‐1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor... 
Irinotecan | S‐1 | 1A1 | UGT | 38 | Breast Cancer | circulating endothelial cells | SN-38 | UGT1A1 | S-1 | CELLS | SOLID TUMORS | SEVERE NEUTROPENIA | COMBINATION | METRONOMIC CHEMOTHERAPY | POLYMORPHISMS | GENE | ONCOLOGY | ANTHRACYCLINE | COLORECTAL-CANCER | JAPANESE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Glucuronosyltransferase - genetics | Breast Neoplasms - enzymology | Neoplasm Metastasis | Pharmacogenomic Variants | Adult | Camptothecin - administration & dosage | Female | Oxonic Acid - pharmacokinetics | Camptothecin - analogs & derivatives | Endothelial Progenitor Cells - metabolism | Camptothecin - pharmacokinetics | Camptothecin - adverse effects | Pharmacogenetics | Drug Administration Schedule | Endothelial Progenitor Cells - drug effects | Gene Frequency | Japan | Tegafur - adverse effects | Neoplasm Recurrence, Local | Treatment Outcome | Oxonic Acid - administration & dosage | Antigens, CD34 - blood | Breast Neoplasms - drug therapy | Tegafur - pharmacokinetics | Oxonic Acid - adverse effects | Disease-Free Survival | Homozygote | Phenotype | Breast Neoplasms - genetics | Endothelial Progenitor Cells - pathology | Glucuronosyltransferase - metabolism | Breast Neoplasms - pathology | Tegafur - administration & dosage | Heterozygote | Aged | Drug Combinations | Antimitotic agents | Care and treatment | Cancer patients | Analysis | Oncology, Experimental | Breast cancer | Genetic aspects | Research | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Cancer Science, ISSN 1347-9032, 06/2019, Volume 110, Issue 6, pp. 1987 - 1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively... 
eGFR | S‐1 | clearance | 5‐fluorouracil | CDHP | Nausea - chemically induced | Area Under Curve | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Stomach Neoplasms - metabolism | Male | Glomerular Filtration Rate - drug effects | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Aged, 80 and over | Adult | Female | Renal Insufficiency - complications | Oxonic Acid - pharmacokinetics | Renal Insufficiency - drug therapy | Stomach Neoplasms - complications | Administration, Oral | Tegafur - adverse effects | Renal Insufficiency - metabolism | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Tegafur - pharmacokinetics | Oxonic Acid - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Fluorouracil - pharmacokinetics | Drug Combinations | Cohort Studies | TEGAFUR | PREDICTION | 5-fluorouracil | CANCER-PATIENTS | PLASMA | ONCOLOGY | S-1 | DISEASE | CREATININE | POTASSIUM OXONATE | EQUATION | Analysis | Fluorouracil | Medical research | Renal function | Statistical analysis | Epidermal growth factor receptors | Toxicity | Patients | Glomerular filtration rate | Studies | Chemotherapy | Hospitals | Clinical medicine | Kidney diseases | Pharmaceutical industry | Drug dosages | Cancer | Original
Journal Article
Angiogenesis, ISSN 0969-6970, 6/2012, Volume 15, Issue 2, pp. 275 - 286
To evaluate UFT and cyclophosphamide (CTX) based metronomic chemotherapy plus celecoxib (CXB) for the treatment of patients with heavily pre-treated advanced... 
GHB | UFT | Gastrointestinal cancer patients | Oncology | Pharmacodynamic biomarkers | Biomedicine general | Cell Biology | Angiogenesis | Cyclophosphamide | Biomedicine | Metronomic chemotherapy | Cancer Research | Ophthalmology | Cardiology | Pharmacokinetics | SOLID TUMORS | DIHYDROPYRIMIDINE DEHYDROGENASE | TEGAFUR | METASTATIC COLORECTAL-CANCER | BREAST-CANCER | GASTRIC-CANCER | ENDOTHELIAL-CELLS | POSTOPERATIVE ADJUVANT CHEMOTHERAPY | VE-CADHERIN | PERIPHERAL VASCULAR DISEASE | ORAL CYCLOPHOSPHAMIDE | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Vascular Endothelial Growth Factor A - blood | Male | Celecoxib | Tegafur - pharmacokinetics | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Uracil - administration & dosage | Gastrointestinal Neoplasms - blood | Aged, 80 and over | Tegafur - administration & dosage | Female | Aged | Cyclophosphamide - pharmacokinetics | Pyrazoles - pharmacokinetics | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Gastrointestinal cancer | Patient outcomes | Dosage and administration | Research | Properties | Drug therapy | Index Medicus | Original Paper
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 6/2019, Volume 24, Issue 6, pp. 660 - 665
S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. Recently,... 
Medicine & Public Health | S-1 | Oncology | Cancer Research | Pharmacokinetics | Surgical Oncology | Gastric cancer | Watering eyes | CISPLATIN | ONCOLOGY | PHASE-III | CHEMOTHERAPY | Original
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1639 - 1650
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2002, Volume 38, Issue 3, pp. 349 - 358
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 04/2008, Volume 83, Issue 4, pp. 589 - 594
Journal Article